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Previous genome-wide association studies (GWAS) for smoking 
behavior (Supplementary Table 1) have identified a chromosome-15 
nicotinic acetylcholine receptor gene cluster as being associated with 
smoking quantity3. The Tobacco and Genetics (TAG) Consortium 
conducted GWAS meta-analyses across 16 studies originally designed 
to evaluate other phenotypes (for example, cardiovascular disease and 
type 2 diabetes). We examined four carefully harmonized smoking 
phenotypes (see Online Methods)—smoking initiation (ever versus 
never been a regular smoker), age of smoking initiation, smoking 
quantity (number of cigarettes smoked per day, CPD) and smok-
ing cessation (former versus current smokers)—among people of 
European ancestry (Table 1). Smoking cessation contrasted former 
versus current smokers, where current smokers reported at interview 
that they presently smoked and former smokers had quit smoking at 
least 1 year before interview. Smokers who had quit smoking for less 
than 1 year at interview were excluded from the analysis to minimize 
 misclassification, as relapse after initial smoking cessation occurs in 
70% to 80% of former smokers within the first year4.
The 16 TAG studies performed their own genotyping, quality con-
trol and imputation (see Supplementary Tables 2 and 3 and Online 
Methods). Studies ranged in size from n = 585 to n = 22,037 and were 
genotyped on six different platforms. Genotype imputation5 resulted 
in a common set of ~2.5 million SNPs (Supplementary Table 3). 
Imputed allele dosages for each SNP (that is, the number of copies 
of the minor allele) were tested for association with each smoking 
phenotype, using an additive model.
We performed a fixed-effect meta-analysis for each smoking pheno-
type by computing pooled inverse variance–weighted β coefficients, s.e. 
values and z-scores for each SNP6. Fixed-effects analyses are regarded 
as the most efficient method for discovery in the GWAS setting7,8. 
Heterogeneity across studies was investigated using the I2 statistic9. 
Random-effects analyses are presented in Supplementary Table 4. 
We used a significance threshold of P < 5 × 10−8 (refs. 10,11).
In the initial TAG meta-analysis, only one locus contained SNPs 
that exceeded genome-wide significance for one of the four pheno-
types (Fig. 1 and Supplementary Table 4). A total of 130 SNPs in the 
15q25.1 nicotinic receptor gene cluster were significantly associated 
with CPD (n = 38,181, minimum P = 4.2 × 10−35 at rs12914385 in 
CHRNA3). One SNP approached significance for smoking cessation 
(n = 41,278, minimum P = 5.5 × 10−8 for rs7872903, located ~17 kb 
5′ of DBH on chromosome 9). No SNPs were significantly associated 
with ever versus never regular smokers (n = 74,035, minimum 
P = 2.2 × 10−7 at rs16941640 in CDC27) or age of smoking initiation 
(n = 24,114, minimum P = 1.6 × 10−6 at rs2806464, located 3′ of 
DISC1) in the initial TAG meta-analysis.
To follow up associations identified in the TAG Consortium analyses, 
we partnered with the ENGAGE and Oxford-GlaxoSmithKline 
(Ox-GSK) consortia and conducted a reciprocal exchange of sum-
mary results for the 15 most significant genetic regions for three 
smoking phenotypes12,13. Our regions were defined by clusters of 
P values < 10−4 (that is, where the correlations (r2) were >0.5 and/or 
the SNPs were located <50 kb apart; Supplementary Table 5). Sample 
sizes across the three consortia were n = 143,023 for smoking initia-
tion, n = 73,853 for CPD and n = 64,924 for smoking cessation 
(data on age of smoking initiation were not available in ENGAGE 
or Ox-GSK).
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Results of the most significant SNPs for each smoking phenotype 
across the three consortia are summarized in Table 2. We identified 
three loci associated with CPD. The synonymous SNP rs1051730 
in CHRNA3 showed the strongest association: each copy of the 
A allele corresponded to an increase in smoking quantity of 1 CPD 
(β = 1.03, s.e. = 0.056, P = 2.8 × 10−73, I2 = 0.66; Fig. 2) and accounted 
for 0.5% of the variance in CPD. The SNP rs16969968[G], which 
has been proposed as a causal variant in this region14, was the sec-
ond most significant SNP associated with CPD (P = 5.57 × 10−72; 
Supplementary Fig. 1). In tests of association for SNPs within the 
table 1 Descriptive characteristics of the 16 studies participating in the tAG Consortium
Study n (% female) Agea, mean (s.d.) Ever smokers (%) CPD, mean (s.d.)b
Age of initiation of smokinga,  
mean (s.d.)b Former smokers (%)b
Population-based cohort studies
Atherosclerosis Risk in Communities (ARIC) 8,330 (52.9) 54.3 (5.7) 60.4 21.0 (11.7) 18.6 (5.1) 57.4
Baltimore Longitudinal Study of Aging (BLSA) 856 (46.0) 48.1 (17.8) 54.0 NA 19.3 (5.9) NA
Cardiovascular Health Study (CHS) 3,236 (60.8) 72.3 (5.4) 52.3 17.8 (11.8) 19.6 (6.6) 77.8
Invecchiare in Chianti (InCHIANTI) 1,200 (55.2) 68.4 (15.5) 43.9 14.8 (9.4) 32.2 (16.7) 57.0
Rotterdam Study 5,610 (60.3) 69.1 (8.9) 59.2 15.8 (11.7) 20.4 (8.2) 62.6
Framingham Heart Study (FHS) 7,257 (53.7) 45.4 (10.9) 54.2 15.5 (10.8) 17.9 (4.2) 61.7
Women’s Genome Health Study (WGHS) 22,037 (100) 54.7 (7.1) 49.2 16.0 (11.0) NA 75.2
Case-control studies
Atherosclerotic Disease Vascular Function and Genetic  
Epidemiology (ADVANCE)
585 (58.8) 45.8 (5.9) 47.7 13.1 (14.2) 17.0 (4.6) 65.2
Atherosclerosis, Thrombosis and Vascular Biology Italian  
Study Group (ATVB)
3,260 (11.6) 39.6 (4.9) 68.1 23.4 (14.7) 17.4 (4.0) 21.3
Diabetes Genetic Initiative (DGI) 2,504 (50.0) 61.6 (10.6) 37.7 NA 19.0 (5.5) NA
Finland-United States Investigation of NIDDM Genetics  
(FUSION)
1,055 (52.8) 64.0 (7.5) 46.8 16.3 (12.4) 21.0 (7.0) 65.0
International Agency for Research on Cancer (IARC) 8,381 (24.7) 59.6 (10.1) 75.2 19.3 (12.9) 18.7 (5.6) 31.4
Myocardial Infarction Genetics Consortium (MIGen) 2,647 (38.5) 48.8 (8.2) 64.3 NA NA 41.1
Nurses’ Health Study (NHS) 2,249 (100) 70.5 (6.4) 53.8 18.5 (10.5) 19.6 (3.6) 88.7
Netherlands Twin Registry-Netherlands Study of Depression 
and Anxiety (NTR/NESDA)
3,438 (66.9) 43.8 (13.4) 64.9 14.5 (9.8) 16.4 (4.2) 52.6
MGS (GAIN):controls 1,390 (54.1) 51.1 (17) 55.9 19.3 (16.4) NA 62.9
aAge in years. bCalculated among ever regular smokers. NA, not available.
a
b
c Ever versus neversmokers
Former versus current
smokers
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Figure 1 Genome-wide association results for the TAG Consortium. Manhattan plots showing significance of association of all SNPs in the TAG 
Consortium meta-analyses for four smoking phenotypes. (a–d) Manhattan plots show SNPs plotted on the x axis according to their position on each 
chromosome against, on the y axis (shown as −log10 P value), the association with CPD (a), former versus current smoking (b), ever versus never 
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15q25.1 region conditional on rs1051730, we observed residual asso-
ciations, with the most significant signals at rs684513[G] (P = 6.3 × 
10−9), in CHRNA5, and rs9788682[G] (P = 1.06 × 10−8) and 
rs7163730[G] (P = 1.22 × 10−8), in LOC123688 (Supplementary 
Fig. 2 and Supplementary Table 6). Our results suggest that several 
markers within this region may influence CPD independently. Fine 
mapping and the use of the 1000 Genomes Project data should help 
refine these signals. We investigated whether the 15q25.1 region 
was associated with smoking initiation and smoking cessation as 
well, but no SNP in that region exceeded genome-wide signifi-
cance (smoking initiation minimum P = 0.98; smoking cessation 
minimum P = 1.75 × 10−5).
table 2 Meta-analytic results from three GWAs smoking consortia
SNP Alleles
TAG meta-analysis Ox-GSK meta analysis ENGAGE meta analysis Combined results
Coded AF n β s.e. P value n β s.e. P value n β s.e. P value n β s.e. P value
CPDa: CHRNA3
rs1051730 G/A 0.65 38,181 −1.0207 0.086 8.00 × 10−33 14,952 −1.1593 0.139 8.88 × 10−17 20,720 −0.9648 0.089 2.15 × 10−27 73,853 −1.0209 0.056 2.75 × 10−73
rs16969968 G/A 0.65 38,181 −1.0150 0.085 4.48 × 10−33 14,952 −1.1153 0.137 3.72 × 10−16 20,720 −0.9426 0.089 2.07 × 10−26 73,853 −1.0029 0.056 5.57 × 10−72
CPDa: in LOC100188947
rs1329650 T/G 0.28 38,181 −0.4317 0.091 2.33 × 10−6 14,952 −0.2568 0.145 7.61 × 10−2 20,720 −0.3464 0.092 1.73 × 10−4 73,853 −0.3673 0.059 5.67 × 10−10
rs1028936 C/A 0.18 37,284 −0.5545 0.116 1.57 × 10−6 14,952 −0.2451 0.176 1.65 × 10−1 20,720 −0.4252 0.113 1.77 × 10−4 72,956 −0.4464 0.074 1.29 × 10−9
CPDa: EGLN2, near CYP2A6
rs3733829 G/A 0.36 38,181 0.3538 0.090 7.67 × 10−5 14,952 0.0477 0.145 7.43 × 10−1 20,720 0.4204 0.089 2.90 × 10−6 73,853 0.3328 0.058 1.04 × 10−8
smoking initiation (ever versus never smokers): BDNF
rs6265 T/C 0.21 74,035 −0.0630 0.015 1.72 × 10−5 34,226 −0.0448 0.022 4.48 × 10−2 34,762 −0.0762 0.024 1.39 × 10−3 143,023 −0.0614 0.011 1.84 × 10−8
rs1013442 T/A 0.26 74,035 −0.0568 0.014 3.39 × 10−5 34,226 −0.0386 0.021 6.36 × 10−2 34,762 −0.0674 0.020 9.60 × 10−4 143,023 −0.0551 0.010 3.31 × 10−8
rs4923457 T/A 0.23 74,035 −0.0600 0.014 2.08 × 10−5 34,226 −0.0421 0.022 5.05 × 10−2 34,762 −0.0752 0.024 1.91 × 10−3 143,023 −0.0586 0.011 3.33 × 10−8
rs4923460 T/G 0.23 74,035 −0.0598 0.014 2.22 × 10−5 34,226 −0.0427 0.022 4.81 × 10−2 34,762 −0.0734 0.024 2.51 × 10−3 143,023 −0.0583 0.011 4.08 × 10−8
rs4074134 T/C 0.23 74,035 −0.0603 0.014 1.90 × 10−5 34,226 −0.0421 0.022 5.08 × 10−2 34,762 −0.0725 0.024 2.81 × 10−3 143,023 −0.0582 0.011 4.11 × 10−8
rs1304100 G/A 0.26 74,035 −0.0557 0.014 4.86 × 10−5 34,226 −0.0460 0.021 2.62 × 10−2 34,762 −0.0651 0.022 2.88 × 10−3 143,023 −0.0554 0.010 4.44 × 10−8
rs6484320 T/A 0.24 74,035 −0.0597 0.014 2.04 × 10−5 34,226 −0.0387 0.021 6.78 × 10−2 34,762 −0.0723 0.024 2.13 × 10−3 143,023 −0.0571 0.010 4.91 × 10−8
rs879048 C/A 0.23 74,035 −0.0598 0.014 2.28 × 10−5 34,226 −0.0409 0.022 5.86 × 10−2 34,762 −0.0728 0.024 2.41 × 10−3 143,023 −0.0578 0.011 4.94 × 10−8
smoking cessation (former versus current smokers): near DBH
rs3025343 G/A 0.84 41,278 0.1177 0.026 5.68 × 10−6 23,646 0.1295 0.041 1.76 × 10−3 NA NA NA NA 64,924 0.1210 0.022 3.56 × 10−8
All SNPs coded to NCBI Build 36/UCSC hg18 forward strand. Coded allele frequency refers to the allele analyzed as the predictor allele; it is not necessarily the minor allele. For CPD, 174 SNPs followed up across three consortia; 
130 exceeded genome-wide significance and the two top SNPs are presented. NA, not available.  
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Figure 2 Forest and regional plots of significant associations for CPD from meta-analyses of the TAG, Ox-GSK and ENGAGE consortia. (a–f) Regional 
association plots show SNPs plotted by position on chromosome against −log10 P value with each smoking phenotype. Estimated recombination rates 
(from HapMap-CEU) are plotted in light blue to reflect the local LD structure on a secondary y axis. The SNPs surrounding the most significant SNP  
(red diamond) are color coded to reflect their LD with this SNP (using pairwise r 2 values from HapMap-CEU): blue, r 2 ≥ 0.8–1.0; green, 0.5–0.8, 




























444  VOLUME 42 | NUMBER 5 | MAY 2010 Nature GeNetics
l e t t e r s
In addition, markers within regions on 
chromosomes 10q23 and 19q13 were sig-
nificantly associated with CPD. The SNPs 
rs1329650[G] (β = 0.367, s.e. = 0.059, 
P = 5.7 × 10−10; Fig. 2) and rs1028936[A] 
(β = 0.446, s.e. = 0.074, P = 1.3 × 10−9; 
Supplementary Fig. 1) are located in a non-
coding RNA (LOC100188947), where each 
additional copy of a risk allele corresponded 
to an increase in smoking quantity of ~0.5 
CPD. Linkage disequilibrium (LD) between 
these SNPs is moderate (r 2 = 0.46), suggest-
ing that they may represent one signal. To 
our knowledge, this region has not been previously investigated in 
relation to smoking behavior or other addiction phenotypes.
The third locus identified for CPD lies in the first intron of EGLN2 
on chromosome 19q13, 40 kb from the 3′ end of CYP2A6. One SNP, 
rs3733829, exceeded genome-wide significance, and each copy of the 
G allele corresponded to an increase in smoking quantity of <0.5 
CPD (β = 0.333, s.e. = 0.058, P = 1.0 × 10−8; Fig. 2). CYP2A6 is an 
established candidate gene for smoking, as it encodes for an enzyme 
involved in the metabolic inactivation of nicotine to cotinine15. 
Many allelic variants of CYP2A6 result in slower metabolism of 
nicotine16 and are associated with lower prevalence of smoking and 
lower amounts of cigarette use16,17. We interpret this finding with 
caution, as only one SNP upstream of CYP2A6 was observed and the 
strength of its association was moderate. However, the 19q13 region 
merits continued investigation given its biological plausibility as 
involved in nicotine metabolism and because several markers within 
this region were identified in the ENGAGE Consortium12. The SNP 
identified in our study (rs3733829) lies directly between, and shows 
moderate LD with, the two most significant markers identified 
in ENGAGE.
Eight SNPs around BDNF exceeded genome-wide significance for 
smoking initiation analyses across the three consortia (Fig. 3). The 
minimum P value was at the missense variant rs6265 (P = 1.8 × 10−8) 
located in the first exon of BDNF on chromosome 11. Each copy 
of rs6265[C] conferred a 6% increase in the relative risk of regular 
smoking (OR = 1.06, 95% c.i. 1.04–1.08); rs6265 accounted for 0.03% 
of the variance. BDNF belongs to a family of neurotrophins that 
regulate synaptic plasticity and survival of cholinergic and dopamin-
ergic neurons18. The eight SNPs overlap an antisense transcript 
(BDNFos). BDNF is expressed at high levels in the prefrontal cortex 
and hippocampus, which are brain regions implicated in the 
cognitive-enhancing effects of nicotine19. Although the molecular 
mechanisms underlying this association have yet to be elucidated, it 
is plausible that genetic variation at BDNF could alter the rewarding 
effects of nicotine through modulation of dopamine reward circuits 
and could contribute to the salience of nicotine’s effects by altering 
formation of drug-related memories that promote continued use 
after initial exposure. The SNP rs6265 has been found to be associ-
ated with substance-related disorders, eating disorders and schizo-
phrenia20. Most recently, it was identified in a GWAS for body mass 
index21; the allele associated with a greater body mass index was the 
same allele associated with regular smoking in our study.
For smoking cessation, one SNP, located 23 kb 5′ of DBH on 
chromosome 9, achieved genome-wide significance: rs3025343[G] 
was associated with former smoking status (OR = 1.12, 95%  
c.i. 1.08–1.18, P = 3.6 × 10−8; Fig. 3) and accounted for 0.19% of the 
variance in smoking cessation. Because DBH catalyzes conversion 
of dopamine to norepinephrine, there has been interest in DBH as a 
candidate gene for various psychiatric phenotypes, including smoking 
behavior22. Although the SNP identified in this study does not cause 
amino acid residue changes in DBH, gene expression may be modified 
either directly or through other variant(s) in strong LD. This view is 
supported by evidence that a genetic variant (C1021T or rs1611115), 
located upstream of the DBH translational start site, accounts for 51% 
of the variation in plasma-DBH activity in European-Americans22. 
Alternatively, the SNP identified in our study or a variant in LD may 
influence expression of other genes nearby (ADAMTSL2, FAM163B 
or SARDH), which would introduce new pathways to our current 
understanding of addiction biology.
To our knowledge, the sample sizes for the TAG Consortium 
alone and combined with the ENGAGE and Ox-GSK consortia are 
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Figure 3 Forest and regional plots of significant 
associations for smoking behavior. (a–d) Shown 
are plots for smoking initiation (a,b) and smoking 
cessation (c,d) from meta-analyses of the TAG, 
Ox-GSK and ENGAGE consortia. Regional 
association plots show SNPs plotted by position 
on the chromosome against −log10 P value 
with each smoking phenotype. Estimated 
recombination rates (from HapMap-CEU) are 
plotted in light blue to reflect the local LD 
structure on a secondary y axis. The SNPs 
surrounding the most significant SNP (red 
diamond) are color coded to reflect their LD with 
this SNP (using pairwise r 2 values from HapMap 
CEU): blue, r 2 ≥ 0.8–1.0; green, 0.5–0.8; 
orange, 0.2–0.5; gray, <0.2. The gray bars at 
the bottom of the plot represent the relative size 
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most of the loci identified in this study reside in or near known can-
didate genes involved in the neurobiology of smoking, which dif-
fers from the results of previous GWAS, in which variants identified 
have generally not been in regions previously suspected. The lack of 
findings for smoking initiation and cessation is noteworthy in light 
of considerable genetic epidemiological data suggesting a role for 
genetic factors in different aspects of smoking behavior (for exam-
ple, heritability estimates are often >0.50)1, and we note that the loci 
identified do not of themselves account for more than small fractions 
of the phenotypic heritability. Additional smoking behavior loci may 
be identified with improved genomic coverage and analysis of gene-
gene and gene-environment interaction, copy number variation or 
epigenetic effects. We acknowledge that imprecision in phenotypic 
assessment and differences across studies could have added noise suf-
ficient to blur all but the most prominent genetic signals. Smoking 
behavior obtained by questionnaires may be subject to phenotypic 
misclassification. Recent work24 has shown that genetic variation at 
15q25.1 influences cotinine (the main and long-lived metabolite of 
nicotine) measurements more strongly than it influences CPD values 
obtained by means of a questionnaire. Future smoking GWAS that 
use biomarkers or longitudinal assessments that refine phenotypic 
assessments by incorporating time to quitting or relapsing to smoking 
may be required. In addition, inclusion of multiple ethnic groups will 
enhance the investigation of the genetics of smoking.
Notably, the five significant loci identified in these meta-analyses 
were each associated with only one specific smoking phenotype. Our 
findings suggests that separate genetic loci contribute modestly to 
phenotypic variability in each aspect of smoking behavior, which, in 
turn, may have implications for the way in which smoking cessation 
therapies and tobacco control efforts are designed and targeted.
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Phenotype harmonization and selection. We spent substantial effort harmo-
nizing the smoking phenotypes across studies. Briefly, first, we created the 
Phenotype Working Group (PWG) to address these crucial issues. Second, we 
obtained English versions of the exact smoking-related questions, responses 
and summary data from each study. These were entered into a master database 
and examined for completeness, outliers and distributions of all smoking vari-
ables. Third, we produced a list of candidate smoking phenotypes available from 
each study. Fourth, as has been recommended25, we calculated heritabilities and 
intercorrelations between the candidate smoking variables using data from the 
Swedish Twin Registry26,27 and the Finnish Twin Cohort Study28,29, two popula-
tion-based twin registries containing extensive smoking data. Finally, the PWG 
integrated all these data to derive the operational phenotypes to be used in the 
meta-analyses.
The central criteria were that a candidate phenotype had to (i) be exactly 
or nearly exactly assessed in nearly all studies, (ii) have distributional proper-
ties similar across studies and conducive to meta-analyses (for example, suf-
ficiently prevalent to allow reasonable statistical power), (iii) have reasonable 
heritability so that genetic analysis was suitable and (iv) have face validity to 
senior researchers in the field.
These analyses yielded unexpected results. For example, the Fagerström Test 
for Nicotine Dependence is commonly used in the field, as either a continu-
ous or dichotomized variable. However, item-level twin analyses showed it to 
be a composite measure of some items with high heritability (for example, 
CPD) but some items with heritability near zero and with important common 
environmental effects (unpublished data).
We examined three elements of smoking behavior: smoking initiation, 
smoking heaviness and smoking cessation. Smoking initiation was assessed 
in two ways: by contrasting individuals who reported having ever versus never 
smoked regularly, and age of smoking initiation.
Ever versus never regular smokers. Regular smokers were defined as those 
who reported having smoked ≥100 cigarettes during their lifetime and never 
regular smokers were defined as those who reported having smoked between 
0 and 99 cigarettes during their lifetime. This definition is consistent with the 
Centers for Disease Control classification of “ever smoker”30.
Age of smoking initiation. Age of smoking initiation was the reported age 
the participant started smoking cigarettes. Some studies collected the age at 
which the participant first tried smoking, whereas others collected the age 
the participant began smoking regularly. As both variables (age first tried and 
age began smoking regularly) were available in the Swedish Twin Registry, 
we calculated the univariate heritabilities for each variable and the genetic 
correlation between them. We studied only females due to the confounding 
effects of prevalent smokeless tobacco (‘snus’) use in Swedish males31. The 
heritabilities for the two variables were similar and the genetic correlation 
was 0.97, which suggested a great deal of overlap in the genetic contributors to 
each trait and supported the idea of using either value in a general assessment 
of age of smoking initiation in the meta-analysis.
Cigarettes per day. Smoking quantity was assessed as the CPD value. Some 
studies collected the average CPD, whereas other studies collected the maximum 
CPD. Longitudinal data from the Finnish Twin Cohort Study revealed a high 
correlation (>0.71) between these variables over time and supported the idea of 
using either value in a general assessment of CPD in the meta-analysis.
Smoking cessation. Smoking cessation contrasted former versus current 
smokers, where current smokers reported that they smoked at the time of the 
interview and former smokers had quit smoking at least 1 year before the inter-
view. As relapse to smoking is highest within the first year of quitting smoking, 
smokers who had quit smoking for less than 1 year at interview were excluded 
from the analysis. Descriptive characteristics of the 16 studies participating in 
the TAG Consortium are presented in Table 1.
Genotyping and imputation. The 16 TAG studies performed their own geno-
typing, quality control and imputation (Supplementary Tables 2 and 3). Studies 
ranged in size from n = 585 to n = 22,037 and were genotyped on six different 
GWAS platforms. Each study applied its own set of quality control filters, 
which were comparable among studies. Each study excluded SNPs with a call 
rate <89%, <1% minor allele frequency or departure from Hardy-Weinberg 
equilibrium. Subjects were excluded for non-European ancestry using PLINK 
multidimensional scaling32, STRUCTURE33 or EigenSoft principal component 
analysis34. In addition, subjects were excluded for <90% call rate, excess auto-
somal heterozygosity, mismatch between reported and genetically determined 
sex or first- or second-degree relatedness. Genotype imputation5 was used to 
harmonize genotyping across different studies, as well as to infer genotypes for 
SNPs that were not genotyped directly on the platforms but that were genotyped 
on the HapMap-2 CEU samples32. SNP imputation was performed using either 
MACH35, IMPUTE36 or BIMBAM10 v0.9937 and resulted in a common set of 
~2.5 million SNPs after removal of SNPs with minor allele frequency <1% or 
poor imputation performance (Supplementary Table 3). Imputed allele dosages 
for each SNP (that is, the number of copies of the minor allele) were tested for 
association with each smoking phenotype using an additive model.
Study-specific GWAS analysis. Each study conducted uniform cross- 
sectional analyses for each smoking phenotype using an additive genetic model. 
Linear regression was used for quantitative traits (CPD and age of smoking 
initiation), and logistic regression was used for discrete traits (ever versus 
never smokers and former versus current smokers). Age of smoking initiation 
was transformed using the natural logarithm owing to heavy tails and non- 
normality. The dependent variables were the smoking phenotypes and the 
independent variables were the imputed allele dosage for a SNP plus an indica-
tor variable for whether a subject was classified as a case in the primary study. If 
the primary study was case-control in design and the phenotype being studied 
was known to be associated with smoking, we adjusted for case status to reduce 
potential confounding38. Individual study results were corrected for residual 
inflation of the test statistic using genomic control39.
Due to the known differences in the prevalences of the smoking phenotypes 
between the two sexes40, all TAG Consortium analyses were run separately for 
males and females. We then tested whether associations between ~2.5 million 
SNPs and each smoking phenotype differed by sex by meta-analyzing males 
and females separately and performing a t-test of their parameter estimates for 
each SNP using a significance threshold of P < 5 × 10−8 (ref. 41).
Meta-analysis of GWAS results. We performed fixed-effect meta-analysis for 
each smoking phenotype by computing pooled inverse-variance–weighted 
β coefficients, standard errors and z-scores for each SNP6. Fixed effects analyses 
were chosen because they are regarded as the most efficient method for discovery 
in the GWAS setting7,8. Meta-analyses were performed using METAL (see 
URLs). Heterogeneity across studies was investigated using the I2 statistic9. 
We used a significance threshold of P < 5 × 10−8 (refs. 10,11).
In silico follow-up of top regions. To validate potential associations identified 
in the TAG Consortium analyses, we partnered with two other smoking GWAS 
consortia and conducted a reciprocal exchange of the 15 most significant 
genetic regions for each smoking phenotype in each study12,13. Regions were 
defined by SNPs with P values <10−4 that clustered together (r2 > 0.5 and/or 
locations <50 kb apart). The ENGAGE Smoking GWAS Consortium consisted 
of 34,762 individuals and the Ox-GSK Smoking GWAS Consortium consisted 
of 34,226 individuals, making the final sample size across the three consortia 
n = 143,023. Studies that participated in multiple consortia were only repre-
sented once in the final analyses.
URLs. Genetic Computing Cluster, http://www.geneticcluster.org/; METAL, 
http://www.sph.umich.edu/csg/abecasis/metal/.
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